Last reviewed · How we verify
NCT05769660
A Study to Evaluate Safety and Efficacy of BEY1107 in Combination with Temozolomide in Patients with Recurrent or Progressive Glioblastoma Multiforme (GBM)
Phase 1 trial testing BEY1107 in Glioblastoma Multiforme in 12 participants. Currently enrolling.
30 November 2026
Quick facts
| Lead sponsor | BeyondBio Inc. |
|---|---|
| Phase | Phase 1 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | sequential |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 12 |
| Start date | 29 November 2022 |
| Primary completion | 30 November 2026 |
| Estimated completion | 31 December 2026 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
- BEY1107 — full drug profile →
- Temozolomide (temozolomide) — full drug profile →
Conditions studied
- Glioblastoma Multiforme — all drugs for Glioblastoma Multiforme →
Sponsor
BeyondBio Inc. — full company profile →
Who can join
19 and older, any sex, with Glioblastoma Multiforme. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a Phase 1 study to evaluate the maximum tolerated dose, safety and efficacy of BEY1107 in combination with Temozolomide in Patients with Recurrent or Progressive Glioblastoma Multiforme (GBM)
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Advancements in Drug Delivery Systems in Glioblastoma Therapy
Mishra P, Gupta P, Markowska A, Ghavami S, et al · · 2026
Verify or expand the search:
- PubMed search for NCT05769660
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of BEY1107
Trials testing the same drug.
- NCT05093907 — A Study to Evaluate Safety and Efficacy of BEY1107 in Combination with Capecitabine in Patients with Metastatic Colorect · Phase 1, PHASE2 · recruiting
- NCT03579836 — Evaluation of Safety and Efficacy in BEY1107 in Monotherapy Gemcitabine Combination in Patient with Pancreatic Cancer · Phase 1, PHASE2 · recruiting
Other recruiting trials for Glioblastoma Multiforme
Currently open trials in the same condition.
- NCT06466031 — Application of FET-PET in Fusion With MRI in the Treatment of Glioblastoma Multiforme [TYR-GLIO] · NA · recruiting
- NCT06333899 — Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion · EARLY_PHASE1 · recruiting
- NCT05956821 — Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age · Phase 1, PHASE2 · recruiting
- NCT06496971 — A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubbl · Phase 3 · recruiting
- NCT06329570 — Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multif · Phase 1, PHASE2 · recruiting
Other BeyondBio Inc. trials
Trials by the same sponsor.
- NCT05093907 — A Study to Evaluate Safety and Efficacy of BEY1107 in Combination with Capecitabine in Patients with Metastatic Colorect · Phase 1, PHASE2 · recruiting
- NCT04476303 — A Study to Evaluate the Pharmacokinetics and Safety of BEY2153 in Healthy Participants · Phase 1 · completed
- NCT03579836 — Evaluation of Safety and Efficacy in BEY1107 in Monotherapy Gemcitabine Combination in Patient with Pancreatic Cancer · Phase 1, PHASE2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05769660 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by BeyondBio Inc.
- Last refreshed: 10 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05769660.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing